Louise Ligresti, MD

About Me

  • Awards and Honors: Castle Connolly Top Doctors: New York Metro Area, 2011-2016
  • Languages Spoken: English
  • Education: MD, SUNY Syracuse
  • Residencies: Internal Medicine - New York Hospital/Weill Cornell Medical College
  • Fellowships: Hematology/Oncology - Memorial Sloan Kettering Cancer Center
  • Board Certifications: Medical Oncology; Hematology

New Patient Appointments

Making an appointment

Call 800-525-2225


Riccio L, Hudis C, Holmes F, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Maickel N, Usakewicz J, Uhlenhopp M, Hortobagyi G, Norton L.  Phase II study of semi-synthetic paclitaxel in patients with metastatic breast cancer previously treated with one chemotherapy regimen.  Proc Am Soc Clin Oncol 15:82, 1996; Poster presentation:  American Society of Clinical Oncology Meeting, Philadelphia, PA, 1996

Plus and Minus IconIcon showing a plus/minus toggle, indicating that the surrounding element can be opened and closed.

Hudis C, Seidman A, Raptis G, Baselga J, Fennelly D, Theodoulou M, Gilewski T, Currie V, Moynahan M, Surbone A, Sklarin N, Robles M, Riccio L, Yao TJ, Uhlenhopp M, Norton L.  Sequential dose-dense Doxorubicin (A)-Paclitaxel (P)-Cyclophosphamide (C) is less toxic than A-concurrent T+C as adjuvant therapy in resected node positive breast cancer.  Proc Am Soc Clin Oncol 15:8, 1996

Riccio L, Hudis C, Seidman A, Baselga J, Currie V, Fennelly D, Gilewski T, Lebwohl D, Moynahan M, Raptis G, Surbone A, Sklarin N, Yao TJ, Keefe D, and Norton L.  Lack of increased cardiac toxicity with sequential doxorubicin and paclitaxel.  Cancer Invest 1998; 16(2):67-71

Hudis C, Fornier M, Riccio L, Lebwohl D, Crown J, Gilewski T, Surbone A, Currie V, Seidman A, Reichman B, Moynahan M, Raptis G, Sklarin N, Theodoulou M, Weiselberg L, Salvaggio R, Panageas DS, Yao TJ, and Norton L.  5-Year Results of Dose-Intensive Sequential Adjuvant Chemotherapy for Women with High-Risk Node-Positive Breast Cancer:  A Phase II Study.  J Clin Oncol 1999 Apr; 17(4):1118

Clinical Trials

As home to one of the world’s top cancer research centers, Memorial Sloan Kettering is typically involved in more than 900 clinical trials at a given time. Currently, clinical trials focused on the conditions I treat are enrolling new patients. If you’re interested in joining a clinical trial, click to learn about the trial’s purpose, eligibility criteria, and how to get more information.

Learn more


Most major health insurers offer plans that include MSK as one of their in-network providers. If MSK is in-network, it means all our doctors are too. Medicaid and New York State Medicare also provide benefits for care at MSK.

Learn more